Krzysztof Składowski

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

Jan B. Vermorken, Jan Stöhlmacher-Williams, Lisa Licitra et al. · The Lancet Oncology · 2013 · 432 citations · Full text

Metastatic Squamous-cell Carcinoma, Open-label Phase 3, Medicine +8

Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines

Vincent Grégoire, Mererid Evans, Quynh‐Thu Le et al. · Radiotherapy and Oncology · 2017 · 379 citations · Full text

Medicine, Ncic Ctg, Nasopharyngeal Cancer +10

Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study

Quynh‐Thu Le, Harold E. Kim, Charles Schneider et al. · Journal of Clinical Oncology · 2011 · 184 citations

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial

J. Giralt, José Trigo, Sandra Nuyts et al. · The Lancet Oncology · 2015 · 172 citations

Neuro-oncology, Radiation Medicine, Open-label Phase 2 +12